Peroxisome Proliferator-Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies

Chemical Biology and Drug Design

Volumn , Issue , 2016, Pages 17-25

  Yousefi, Bahman ^a,b,c   Samadi, Nasser ^b,c   Baradaran, Behzad ^a   Shafiei Irannejad, Vahid ^a,c   Zarghami, Nosratollah ^b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cancer; chemotherapy; chronic myeloid leukemia; peroxisome proliferator activated receptors

Indexed keywords

IMATINIB; LIGAND; ORGANIC CATION TRANSPORTER 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DRUG STRUCTURE; HUMAN; NEOPLASM; PRIORITY JOURNAL; REVIEW;

EID: 84973922761     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12737     Document Type: Review

References (91)

1. Grommes C., Landreth G.E., Heneka M.T. (2004) Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists. Lancet Oncol;5:419–429.
2. Yao P.L., Morales J.L., Zhu B., Kang B.H., Gonzalez F.J., Peters J.M. (2014) Activation of peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) inhibits human breast cancer cell line tumorigenicity. Mol Cancer Ther;13:1008–1017.
3. Eucker J., Bängeroth K., Zavrski I., Krebbel H., Zang C., Heider U., Jakob C., Elstner E., Possinger K., Sezer O. (2004) Ligands of peroxisome proliferator-activated receptor [gamma] induce apoptosis in multiple myeloma. Anticancer Drugs;15:955–960.
4. Huang H., Wu D., Fu J., Chen G., Chang W., Chow H.C., Leung A.Y., Liang R. (2009) All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. Eur J Haematol;83:191–202.
5. Zang C., Liu H., Posch M.G., Waechter M., Facklam M., Fenner M.H., Ruthardt M. (2004) Peroxisome proliferator-activated receptor γ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res;28:387–397.
6. Hehlmann R., Hochhaus A., Baccarani M. (2007) Chronic myeloid leukaemia. Lancet;370:342–350.
7. Daley G.Q. (2004) Chronic myeloid leukemia. Cell;119:314–316.
8. Gora-Tybor J., Robak T. (2008) Targeted drugs in chronic myeloid leukemia. Curr Med Chem;15:3036–3051.
9. Kota B.P., Huang T.H.-W., Roufogalis B.D. (2005) An overview on biological mechanisms of PPARs. Pharmacol Res;51:85–94.
10. Blanquart C., Barbier O., Fruchart J.C., Staels B., Glineur C. (2003) Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol;85:267–273.
11. Filip-Ciubotaru F., Foia L., Manciuc C., Grigore C. (2010) PPARs: structure, mechanisms of action and control. Rev Med Chir Soc Med Nat Iasi;115:477–484.
12. Hörlein A.J., Näär A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A. (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor.
13. Chen J.D., Evans R.M. (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors.
14. Grabacka M., Pierzchalska M., Reiss K. (2013) Peroxisome proliferator activated receptor a ligands as anticancer drugs targeting mitochondrial metabolism. Curr Pharm Biotechnol;14:342.
15. Nagy L., Schwabe J.W. (2004) Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci;29:317–324.
16. Dowell P., Peterson V.J., Zabriskie T.M., Leid M. (1997) Ligand-induced peroxisome proliferator-activated receptor alpha conformational change. J Biol Chem;272:2013–2020.
17. Moraes L.A., Piqueras L., Bishop-Bailey D. (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther;110:371–385.
18. Bishop-Bailey D., Wray J. (2003) Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat;71:1–22.
19. Yousefi B., Darabi M., Baradaran B., Shekari Khaniani M., Rahbani M., Darabi M., Fayezi S., Mehdizadeh A., Saliani N., Shaaker M. (2012) Inhibition of MEK/ERK1/2 signaling affects the fatty acid composition of HepG2 human hepatic cell line. BioImpacts;2:145–150.
20. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A. (2006) International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev;58:726–741.
21. Berger J.P., Akiyama T.E., Meinke P.T. (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci;26:244–251.
22. Martens F.M.C., Visseren F.L., Lemay J., De Koning E.J., Rabelink T.J. (2002) Metabolic and additional vascular effects of thiazolidinediones. Drugs;62:1463–1480.
23. Saliani N., Darabi M., Yousefi B., Baradaran B., Khaniani M.S., Darabi M., Shaaker M., Mehdizadeh A., Naji T., Hashemi M. (2013) PPARγ agonist-induced alterations in Δ6-desaturase and stearoyl-CoA desaturase 1: role of MEK/ERK1/2 pathway. World J Hepatol;5:220–225.
24. Yki-Järvinen H. (2004) Thiazolidinediones. N Engl J Med;351:1106–1118.
25. Sanderson L.M., Degenhardt T., Koppen A., Kalkhoven E., Desvergne B., Müller M., Kersten S. (2009) Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) but not PPARα serves as a plasma free fatty acid sensor in liver. Mol Cell Biol;29:6257–6267.
26. Duval C., Chinetti G., Trottein F., Fruchart J.C., Staels B. (2002) The role of PPARs in atherosclerosis. Trends Mol Med;8:422–430.
27. Leibowitz M.D., Fievet C., Hennuyer N., Peinado-Onsurbe J., Duez H., Bergera J., Cullinan C.A. (2000) Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett;473:333–336.
28. Charkhpour M., Ghavimi H., Ghanbarzadeh S., Yousefi B., Khorrami A., Mesgari M., Hassanzadeh K. (2015) Protective effect of pioglitazone on morphine-induced neuroinflammation in the rat lumbar spinal cord. J Biomed Sci;5:321–327.
29. Michalik L., Desvergne B., Wahli W. (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer;4:61–70.
30. Tachibana K., Yamasaki D., Ishimoto K., Doi K. (2008) The role of PPARs in cancer. PPAR Res;2008:102737. doi: 10.1155/2008/102737.
31. Issemann I., Green S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature;347:645–650.
32. Kömüves L.G., Hanley K., Lefebvre A.-M., Man M.-Q., Ng D.C., Bikle D.D., Williams M.L. (2000) Stimulation of PPARα promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol;115:353–360.
33. Kömüves L.G., Hanley K., Man M.-Q., Elias P.M., Williams M.L., Feingold K.R. (2000) Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARα activators restores tissue homeostasis. J Invest Dermatol;115:361–367.
34. Hanley K., Kömüves L.G., Ng D.C., Schoonjans K., He S.S., Lau P., Bikle D.D. (2000) Farnesol stimulates differentiation in epidermal keratinocytes via PPARα. J Biol Chem;275:11484–11491.
35. Yasui Y., Kim M., Tanaka T. (2008) PPAR ligands for cancer chemoprevention. PPAR Res;2008:548919. doi: 10.1155/2008/548919.
36. Collett G.P., Betts A.M., Johnson M.I., Pulimood A.B., Cook S., Neal D.E., Robson C.N. (2000) Peroxisome proliferator-activated receptor α is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res;6:3241–3248.
37. Saidi S.A., Holland C.M., Charnock-Jones D.S., Smith S.K. (2006) In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer;5:13.
38. Suchanek K.M., May F.J., Robinson J.A., Lee W.J., Holman N.A., Monteith G.R., Roberts-Thomson S.J. (2002) Peroxisome proliferator–activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog;34:165–171.
39. Tanaka T., Kohno H., Yoshitani S.-I., Takashima S., Okumura A., Murakami A., Hosokawa M. (2001) Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in Rats1. Cancer Res;61:2424–2428.
40. Scatena R., Bottoni P., Botta G., Martorana G.E., Giardina B. (2007) The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol;293:C12–C21.
41. Scatena R., Nocca G., Sole P.D., Rumi C., Puggioni P., Remiddi F., Bottoni P. (1999) Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ;6:781–787.
42. Krishnan A., Nair S.A., Pillai M.R. (2007) Biology of PPARγ in cancer: a critical review on existing lacunae. Curr Mol Med;7:532–540.
43. Girnun G.D., Smith W.M., Drori S., Sarraf P., Mueller E., Eng C., Nambiar P. (2002) APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci USA;99:13771–13776.
44. Kato M., Kusumi T., Tsuchida S., Tanaka M., Sasaki M., Kudo H. (2004) Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol;130:73–79.
45. Burstein H.J., Demetri G.D., Mueller E., Sarraf P., Spiegelman B.M., Winer E.P. (2003) Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat;79:391–397.
46. Qin L., Gong C., Chen A.M., Guo F.J., Xu F., Ren Y., Liao H. (2014) Peroxisome proliferatoractivated receptor gamma agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Mol Med Rep;10:695–700.
47. Yan S., Yang X., Chen T., Xi Z., Jiang X. (2014) The PPARgamma agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. Cancer Gene Ther;21:188–193.
48. Ninomiya I., Yamazaki K., Oyama K., Hayashi H., Tajima H., Kitagawa H., Fushida S. (2014) Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Oncol Lett;8:2709–2714.
49. Leung W., Bai A., Chan V., Yu J., Chan M., To K., Wu J. (2004) Effect of peroxisome proliferator activated receptor γ ligands on growth and gene expression profiles of gastric cancer cells. Gut;53:331–338.
50. Kitamura S., Miyazaki Y., Hiraoka S., Nagasawa Y., Toyota M., Takakura R., Kiyohara T. (2001) PPARγ agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. Int J Cancer;94:335–342.
51. Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. Cancer Lett;179:185–195.
52. Elstner E., Müller C., Koshizuka K., Williamson E.A., Park D., Asou H., Shintaku P. (1998) Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA;95:8806–8811.
53. Konopleva M., Andreeff M. (2002) Role of peroxisome proliferator-activated receptor-γ in hematologic malignancies. Curr Opin Hematol;9:294–302.
54. Yamakawa-Karakida N., Sugita K., Inukai T., Goi K., Nakamura M., Uno K., Sato H. (2002) Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. Cell Death Differ;9:513–526.
55. Yasugi E., Horiuchi A., Uemura I., Okuma E., Nakatsu M., Saeki K., Kamisaka Y. (2006) Peroxisome proliferator-activated receptor γ ligands stimulate myeloid differentiation and lipogenensis in human leukemia NB4 cells. Dev Growth Differ;48:177–188.
56. Schlezinger J.J., Emberley J.K., Sherr D.H. (2006) Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor gamma agonist, and their contribution to GW7845-induced apoptosis. Toxicol Sci;92:433–444.
57. Liu J.-J., Liu P.-Q., Lin D.-J., Xiao R.-Z., Huang M., Li X.-D., He Y. (2007) Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-γ agonists induced apoptosis in human monocyte leukemia cells in vitro. Ann Hematol;86:173–183.
58. Lee Y.-R., Yu H.-N., Noh E.-M., Kim J.-S., Song E.-K., Han M.-K., Kim B.-S. (2007) Peroxisome proliferator-activated receptor γ and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells. Int J Hematol;85:231–237.
59. Simpson-Haidaris P., Pollock S., Ramon S., Guo N., Woeller C., Feldon S., Phipps R. (2010) Anticancer role of PPAR γ agonists in hematological malignancies found in the vasculature, marrow, and eyes. PPAR Res;2010:814609. doi: 10.1155/2010/814609.
60. Nicol C.J., Yoon M., Ward J.M., Yamashita M., Fukamachi K., Peters J.M., Gonzalez F.J. (2004) PPARγ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis;25:1747–1755.
61. Saez E., Rosenfeld J., Livolsi A., Olson P., Lombardo E., Nelson M., Banayo E., Cardiff R.D., Izpisua-Belmonte J.C., Evans R.M. (2004) PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev;18:528–540.
62. Basu-Modak S., Braissant O., Escher P., Desvergne B., Honegger P., Wahli W. (1999) Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. J Biol Chem;274:35881–35888.
63. Granneman J., Skoff R., Yang X. (1998) Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes. J Neurosci Res;51:563–573.
64. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med;346:645–652.
65. Plutzky J. (2000) Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol;15:416–421.
66. Crowe D.L., Chandraratna R. (2004) A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res;6:R546–R555.
67. Strakova N., Ehrmann J., Bartos J., Malikova J., Dolezel J., Kolar Z. (2004) Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma;52:126–136.
68. Panigrahy D., Shen L.Q., Kieran M.W., Kaipainen A. (2003) Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs;12:1925–1937.
69. Greene M.E., Pitts J., Mccarville M.A., Wang X.S., Newport J.A., Edelstein C., Lee F. (2000) PPARgamma: observations in the hematopoietic system. Prostaglandins Other Lipid Mediat;62:45–73.
70. Hirase N., Yanase T., Mu Y.-M., Muta K., Umemura T., Takayanagi R., Nawata H. (2000) Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562. Leuk Res;24:393–400.
71. Lozzio C.B., Lozzio B.B. (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood;45:321–334.
72. Andersson L.C. (1979) Induction of erythroid differentiation in the human leukaemia cell line K562. Nature;278:364–365.
73. Gewirtz A.M., Burger D., Rado T.A., Benz E.J., Hoffman R. (1982) Constitutive expression of platelet glycoproteins by the human leukemia cell line K562. Blood;60:785–789.
74. Hasegawa H., Yamada Y., Komiyama K., Hayashi M., Ishibashi M., Sunazuka T., Izuhara T. (2007) A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Δ12, 14 prostaglandin J2 production. Blood;110:1664–1674.
75. Zang C., Liu H., Waechter M., Eucker J., Bertz J., Possinger K., Koeffler H.P. (2006) Report dual PPARα/γLigand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. Cell Cycle;5:2237–2243.
76. Yousefi B., Samadi N., Baradaran B., Rameshknia V., Shafiei-Irannejad V., Majidinia M., Targhaze N., Zarghami N. (2015) Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Cell Mol Biol;61:118–122.
77. Tontonoz P., Singer S., Forman B.M., Sarraf P., Fletcher J.A., Fletcher C.D., Brun R.P. (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA;94:237–241.
78. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell;93:241–252.
79. Hirase N., Yanase T., Mu Y.-M., Muta K., Umemura T., Takayanagi R., Nawata H. (1999) Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology;57(Suppl. 2):17–26.
80. Liu J.J., Huang R.W., Lin D.J., Peng J., Wu X.Y., Lin Q., Pan X.L. (2005) Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol;16:455–459.
81. Liu J.J., Hu T., Wu X.Y., Wang C.Z., Xu Y., Zhang Y., Xiao R.Z. (2009) Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone–induced apoptosis in leukemia k562 cells and its mechanisms of action. Int J Toxicol;28:123–131.
82. Kuribayashi K., Mayes P.A., El-Deiry W.S. (2006) Journal club what are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther;5:763–765.
83. Kaufmann S.H., Lee S.-H., Meng X.W., Loegering D.A., Kottke T.J., Henzing A.J., Ruchaud S. (2008) Apoptosis-associated caspase activation assays. Methods;44:262–272.
84. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. (1998) A requirement for NF-κB activation in Bcr–Abl-mediated transformation. Genes Dev;12:968–981.
85. Hamdane M., David-Cordonnier M.-H., D'Halluin J.C. (1997) Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene;15:2267–2275.
86. Liu H., Zang C., Fenner M.H., Liu D., Possinger K., Koeffler H.P., Elstner E. (2006) Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood;107:3683–3692.
87. Yousefi B., Samadi N., Ahmadi Y. (2014) Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA Repair;22:24–29.
88. Wang L., Giannoudis A., Austin G., Clark R.E. (2012) Peroxisome proliferator–activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. Exp Hematol;40:811–819 e2.
89. Lewis J.D., Habel L.A., Quesenberry C.P., Strom B.L., Peng T., Hedderson M.M., Ehrlich S.F., Mamtani R., Bilker W., Vaughn D.J., Nessel L., Van Den Eeden S.K., Ferrara A. (2015) Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA;314:265–277.
90. Kanya K., Kazuhiro A., Manato K., Masahiro S., Kyokushin H., Hiroshi M., Satoko K., Yukio N. (2015) Does pioglitazone increase the risk of bladder cancer in japanese diabetic patients. Med Surg Urol;4:2.
91. Prost S., Relouzat F., Spentchian M., Ouzegdouh Y., Saliba J., Massonnet G., Beressi J.P., Verhoeyen E., Raggueneau V., Maneglier B., Castaigne S., Chomienne C., Chrétien S., Rousselot P., Leboulch P. (2015) Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature;525:380–383.